Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial to Evaluate ZD1839 (IRESSA) in Combination With Radiotherapy & Gemcitabine as First-Line Treatment in Patients With Locally Advanced Pancreatic Cancer

NCT00234416 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00234416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00234416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial to Evaluate ZD1839 (IRESSA) in Combination With Radiotherapy & Gemcitabine as First-Line Treatment in Patients With Locally Advanced Pancreatic Cancer
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2002
Completion date
March 31, 2005
Enrollment
45
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer